Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aluminium hydroxide; Malaria vaccine
- Indications Falciparum malaria
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 07 May 2008 Biomarkers information updated
- 06 May 2008 Status changed from initiated to recruiting, according to ClinicalTrials.gov.
- 26 Apr 2008 New trial record.